Related Experiment Video
Updated: Apr 17, 2026
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
2.3K
Reticulocalbin-2 in the Hippocampus Improves Cognitive Function of Diabetic Mice.
Ting Zhang1,2, Simiao Tang2, Jiahui Cheng3
1Jishou University School of Medicine, Jishou, Hunan, China.
Brain and Behavior
|April 16, 2026
Summary
Decreased reticulocalbin-2 (RCN2) in the hippocampus worsens cognitive decline in diabetes, linked to Alzheimer's disease. Boosting RCN2 shows therapeutic potential for neuroprotection.
Area of Science:
- Neuroscience
- Endocrinology
- Genetics
Background:
- Diabetes mellitus is a significant risk factor for Alzheimer's disease (AD).
- The precise molecular mechanisms linking diabetes to AD pathogenesis remain incompletely understood.
- The hippocampus, crucial for memory, is severely affected in both conditions.
Purpose of the Study:
- To elucidate the role of reticulocalbin-2 (RCN2) in the hippocampus.
- To investigate how RCN2 links diabetes to increased Alzheimer's disease risk.
- To explore RCN2 as a potential therapeutic target.
Main Methods:
- Utilized db/db mice to model diabetes-associated cognitive impairment.
- Employed genetic and viral methods for hippocampal RCN2 manipulation (knockdown, deletion, overexpression).
- Assessed cognitive function, synaptic integrity, and the GSK3β-Tau pathway.
Main Results:
- Reduced hippocampal RCN2 expression correlated with cognitive deficits and synaptic damage.
- RCN2 inhibits the GSK3β-Tau pathway, protecting against synaptic loss.
- Hippocampal RCN2 overexpression partially reversed cognitive decline in a diabetic mouse model.
Conclusions:
- Reticulocalbin-2 (RCN2) acts as a crucial neuroprotective protein in the hippocampus.
- Targeting RCN2 offers a promising therapeutic strategy for Alzheimer's disease, especially in diabetic patients.
- RCN2 modulation may mitigate diabetes-induced neurodegeneration.
